By Keith L. Carson
Volume 12, Issue 4 (Winter 2013/2014)
I’ve seen little to tell me the major biopharma firms, or the larger supply firms, have learned anything. They’re stuck on the concepts of slashing vital resources—such as R&D and capacity—to “do deals” plus pay executive bonuses, investment bankers, and hordes of attorneys. As a result, we’ve seen a burgeoning of Business-to-Business (B2B) meetings where the talks are geared toward selling companies and acquisition services. So we continue to see these large firms hoarding cash, acquiring companies, and cutting strategic resources…
Citation: Carson KL. From the Editor-in-Chief: Where’s the Value in These Never-Ending M&As? BioProcess J, 2013; 12(4): 4. https://doi.org/10.12665/J124.Carson
Posted online July 28, 2026